Peregrine Pharmaceuticals (PPHM): Price Target and June Short Interest Disclosure

Peregrine Pharmaceuticals (PPHM) : The most positive equity analysts on Peregrine Pharmaceuticals (PPHM) expects the shares to touch $2, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $1 with an expected fluctuation of $0.5 from the mean.

Peregrine Pharmaceuticals (PPHM) has shown a drop of 82.2% or 7,743,556 shares in the short positions. The bets have increased to 1,676,958 shares on June 30,2016 from 9,420,514 shares on June 15,2016. With respect to the floated shares, the shorts are 0.7%. The days to cover are calculated to be 1, using the standard per day volume of 2,813,391 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.


Peregrine Pharmaceuticals (NASDAQ:PPHM): stock turned positive on Thursday. Though the stock opened at $0.41, the bulls momentum made the stock top out at $0.45 level for the day. The stock recorded a low of $0.388 and closed the trading day at $0.434, in the green by 11.57%. The total traded volume for the day was 2,137,095. The stock had closed at $0.389 in the previous days trading.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.